P16(INK4) expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors

Japanese Journal of Cancer Research

Volumn 88, Issue 10, 1997, Pages 1009-1016

  Fukuoka, Kazuya ^a,b   Adachi, Jun Ichi ^a   Nishio, Kazuto ^a   Arioka, Hitoshi ^a   Kurokawa, Hirokazu ^a   Fukumoto, Hisao ^a   Ishida, Tomoyuki ^a   Nomoto, Taisuke ^a   Yokote, Hideyuki ^a   Tomonari, Akira ^a   Narita, Nobuhiro ^b   Yokota, Jun ^a   Saijo, Nagahiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

DNA topoisomerase I; DNA topoisomerase I inhibitor; Drug sensitivity; Non small cell lung cancer cells; p16(INK4)

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; MESSENGER RNA; PROTEIN P16; 7-ETHYL-10-HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; PROTEIN P16INK4A;

ARTICLE; CELL LEVEL; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA DENATURATION; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG NON SMALL CELL CANCER; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; TUMOR CELL LINE; CELL CULTURE; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; LUNG TUMOR; METABOLISM; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, NORTHERN; BLOTTING, WESTERN; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; HUMANS; LUNG NEOPLASMS; RNA, MESSENGER; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0030609024     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1997.tb00322.x     Document Type: Article

References (37)

1. Lowe, S. W., Ruley, H. E., Jacks, T. and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957-967 (1993).
2. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K. and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature, 368, 753-756 (1994).
3. Kamb, A., Gruis, N. A., Weaver, F. J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. III., Johnson, B. E. and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science, 264, 436-440 (1994).
4. INK4 in human cancer. Proc. Natl. Acad. Sci. USA, 91, 11045-11049 (1994).
5. INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res., 55, 6200-6209 (1995).
6. INK4B/MTS2, andp18 genes in primary and metastatic lung cancer. Cancer Res., 55, 1448-1451 (1995).
7. Nakagawa, K., Conrad, N. K., Williams, J. P., Johnson, B. E. and Kelley, M. J. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. Oncogene, 11, 1843-1851 (1995).
8. Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A., Ally, D. S., Sheahan, M. D., Clark, W. J., Tucker, M. A. and Dracopoli, N. C. Germline p16 mutations in familial melanoma. Nat. Genet., 8, 15-21 (1994).
9. Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J. and Kern, S. E. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet., 8, 27-32 (1994).
10. Mon, T., Miura, K., Aoki, T., Nishihira, T., Mori, S. and Nakamura, Y. Frequent somatic mutation of the MTS1/ CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res., 54, 3396-3397 (1994).
11. INK4 expression in primary lung cancers and cell lines. Cancer Res., 55, 505-509 (1995).
12. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81, 323-330 (1995).
13. INK4. Science, 267, 249-252 (1995).
14. INK4 protein is restricted to the subset of lung cancer lines that retains wild-type RB. Oncogene, 9, 3375-3378 (1994).
15. Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., Levitt, M., Pass, H., Gazdar, A. F. and Minna, J. D. p53: a frequent target for genetic abnormalities in lung cancer. Science, 246, 491-494 (1989).
16. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem., 65, 653-692 (1996).
17. Chen, A. Y. and Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol., 34, 191-218 (1994).
18. Hsiang, Y. H., Hertzberg, R., Hecht, S. and Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260, 14873-14878 (1985).
19. Fukuoka, M., Niitani, H., Suzuki, A., Motomiya, M., Hasegawa, K., Nishiwaki, Y., Kuriyama, T., Ariyoshi, Y., Negoro, S., Masuda, N., Nakajima, S. and Taguchi, T. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol., 10, 16-20 (1992).
20. INK4 gene. Int. J. Oncol., 10, 33-39 (1997).
21. ) Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63 (1983).
22. Deffie, A. M., Batra, J. K. and Goldenberg, G. J. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res., 49, 58-62 (1989).
23. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254 (1976).
24. Liu, L. F. and Miller, K. G. Eukaryotic DNA topoisomerase; two forms of type I DNA topoisomerase from HeLa cell nuclei. Proc. Natl. Acad. Sci. USA, 78, 3487-3491 (1981).
25. Chomczynski, P. and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162, 156-159 (1987).
26. D'Arpa, P., Machlin, P. S., Ratrie, H. III., Rothfield, N. F., Cleveland, D. W. and Earnshaw, W. C. cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment, Proc. Natl. Acad. Sci. USA, 85, 2543-2547 (1988).
27. Madden, K. R. and Champoux, J. J. Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin. Cancer Res., 52, 525-532 (1992).
28. Kanzawa, F., Sugimoto, Y., Minato, K., Kasahara, K., Bungo, M., Nakagawa, K., Fujiwara, Y., Liu, L. F. and Saijo, N. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res., 50, 5919-5924 (1990).
29. Kubota, N., Kanzawa, F., Nishio, K., Takeda, Y., Ohmori, T., Fujiwara, Y., Terashima, Y. and Saijo, N. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochem. Biophys. Res. Commun., 188, 571-577 (1992).
30. Prommier, Y., Tanizawa, A., Okada, K. and Andoh, T. Cellular determinants of sensitivity and resistance to camptothecins. In "Camptothecins: New Anticancer Agents," ed. M. Potmesil and H. Pinedo, pp. 123-138 (1995). CRC Press, Boca Raton, FL.
31. Ohira, T., Nishio, K., Kanzawa, F., Ishida, T., Ohe, Y., Arioka, H., Funayama, Y., Ogasawara, H., Kato, H. and Saijo, N. Hypersensitivity of NIH3T3 cells transformed by H-ras gene to DNA topoisomerase I inhibitors. Int. J. Cancer, 67, 702-708 (1996).
32. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R. and Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science, 246, 1046-1048 (1989).
33. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W. W., Owen, S. L. and Roth, J. A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54, 2287-2291 (1994).
34. Wahl, A. F., Donaldson, K. L., Fairchild, C., Lee, F. Y., Foster, S. A., Demers, G. W. and Galloway, D. A. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med., 2, 72-79 (1996).
35. Hawkins, D. S., Demers, G. W. and Galloway, D. A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56, 892-898 (1996).
36. Ohmori, T., Podack, E. R., Nishio, K., Takahashi, M., Miyahara, Y., Takeda, Y., Kubota, N., Funayama, Y., Ogasawara, H., Ohira, T., Ohta, S. and Saijo, N. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem. Biophys. Res. Commun., 192, 30-36 (1993).
37. Hochhauser, D., Stanway, C. A., Harris, A. L. and Hickson, I. D. Cloning and characterization of the 5′-flanking region of the human topoisomerase II alpha gene. J. Biol. Chem., 267, 18961-18965 (1992).